Oncology Peer Review On-The-Go: 1-on-1 with David Johnson: Enveric’s Endocannabinoid Products for Glioblastoma

Podcast

CancerNetwork®’s podcast features an interview with the chairman and CEO of Enveric Biosciences, David Johnson, to discuss the latest in their development of endocannabinoid products.

In this episode, CancerNetwork® sat down for a conversation with David Johnson, chairman and CEO of Enveric Biosciences. Johnson thoroughly discussed the background of the biosciences company and detailed the endocannabinoid products Enveric is developing to positively impact quality of life for patients with glioblastoma and other cancers.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast anywhere podcasts are available.

Recent Videos
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.
Anyone undergoing cancer treatments could benefit from cancer rehabilitation, according to Jessica Cheng, MD.
Jessica Cheng, MD, noted that working with patients in the field of cancer rehabilitation to improve recovery times brings her joy.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Related Content